of damaged components of the nervous system, neuroplasticity, neuroprotection and neuromodulation, vasculogenesis, and recovery mechanisms of immune regulation (Fornai et al., 2008; IANR, 2009; Mitrecic´ et al., 2009; Huang et al., 2010) . Embryonic or neuronal stem cells hardly replace motor neuron in ALS and also are difficult to have useful functions as people expect. Otherwise, transplanted cells can serve as a source of trophic factors providing neuroprotection, slowing down neuronal degeneration, and disease progression. Presently, cell-based neurorestorative treatment has become a new trend (Huang, 2010) . Rapidly increasing worldwide data have proven that it has a pivotal therapeutic value in ALS (see Tables 1 and 2 ; Chen et al., 2012) . So neruoprotection is one of the most functional neurorestorative strategies for ALS; unfortunately Dr. Piepers fully ignored most of the progress in this research field.
What ideal expectation of treatment is and What current medicine can do for als?
To attenuate the rate of deterioration should be considered and encouraged as the main aim at the current time, because the cure has not yet been made available so far. So any improvement is very important for patients with ALS. Based on Dr. Piepers' paper, we at least found three out of a total of seven patients who had reversed their functions after our treatment. Our recent study, multiple transplantations for ALS shows that every single treatment could make functional improvement for patients ( Table 3 ; Chen et al., 2012) . These essential findings should be translated as highlighted positive results because specialists in the ALS Cell-based neurorestorotherapy in amyotrophic lateral sclerosis -scientific truth should rely on facts, but not conjecture introduction Amyotrophic lateral sclerosis (ALS) is a progressive, fatal, neurodegenerative disease caused by the degeneration of motor neurons, the nerve cells in the central nervous system that control voluntary muscle movement. Death due to respiratory failure occurs typically 2-5 years after disease onset (Suzuki et al., 2007) . Our basic and clinical studies have proven that OECs have neuroprotective effect and can improve quality of life and prolong surviving time (Huang et al., , 2008 Chen et al., 2007 Chen et al., , 2012 Li et al., 2011) . Dr. Piepers (Piepers and van den Berg, 2010 ) published a paper to make comment on our work, in which there were some wrong viewpoints and errors. Also there may be someone sharing same viewpoints with his paper. In order to avoid misleading readers, it is our irresistible duty to tell people the truth what happened about treatment study, show more evidences, and facts of development for this disease. Herein, we encourage people to read his original paper with our thoughts in mind. We strongly believe that scientific truth should rely on facts, but not conjecture.
"these therapies aim at neuronal replacement or use embryonic or neuronal stem cells to prevent dysfunctional motor neurons from dying" is correct?
In fact, the mechanisms for neurorestoration in ALS are very complex, which lie on neural regeneration, repair, and replacement study community around the whole world know there is no way to reverse the clinical course of ALS through routine treatment including Rilutek. People should not require current medicine to get treatment results as their ideal expectation for some untreatable diseases such as ALS.
Where should the cells be transplanted into?
We can understand why Dr. Piepers said that "it is difficult to understand how focal injection of OECs into the corona radiata of ALS patients would result in improved function of motor neurons that are not in close proximity to the injection site." We compared two ways by transplanting cells into spinal cord or brain; and there was no difference of functional improvement between two methods (Chen et al., 2007) . We are also doing experimental study which will be published soon. People will know more about the progress in this field from our current experimental study, that is, OEC transplantation in corona radiate prolongs the survival of SOD1-G93A rats with protection to not only the upper motor neurons but lower motor neurons in cornu anterius medullae spinalis as well.
"it has been shoWn that injecting stem cells into the spinal cord of als patients is technically feasible and safe" is correct?
It is well known that the spinal cord surgery under the general anesthesia has more risks in ALS patients, so we have improved our treatment from the initial intraspinal cord transplantation since over 5 years ago. Our clinical study proved that local anesthesia and stereotactic procedure has much less body damage for ALS patients (Chen et al., 2007) . We suggest that Dr. Piepers should do more clinical investigations or get clinical experience before he comments or discusses on which method is better, feasible, and safe for clinical issue.
immunosuppressant is necessary?
The application of immunosuppressant remains controversial after cell transplantation into the brain and/or spinal cord. In additional, some of the ALS patients are too weak to tolerate the drugs. Most recently, OECs were able to stay alive for at least 12-24 months which has been proven through two autopsies by Italian physicians (Giordana et al., 2010) . In summary, to talk by conjecture is a simple process; however, to really help patients with ALS to improve their neurological functions and quality of life must face (1996) . Intraspinal injection of embryonic neurons maintains muscle phenotype in adult chronic spinal rats. J. Neurosci. Res. 46, [324] [325] [326] [327] [328] [329] Beers, D. R., Henkel, J. S., Zhao, W., Wang, J., and Appel, S. H. (2008) . CD4+ T cells support glial neuroprotection, slow disease progression, and modify glial morphology in an animal model of inherited ALS. Proc. Natl. Acad. Sci. U.S.A. 105, 15558-15563. Cashman, N., Tan, L. Y., Krieger, C., Mädler, B., Mackay, A., Mackenzie, I., Benny, B., Nantel, S., Fabros, M., Shinobu, L., Yousefi, M., and Eisen, A. (2008) . Pilot study of granulocyte colony stimulating factor (G-CSF)-mobilized peripheral blood stem cells in amyotrophic lateral sclerosis (ALS). Muscle Nerve 37, 620-625. Chen, L., Chen, D., Xi, H., Wang, Q., Liu, Y., Zhang, F., Wang, H., Ren, Y., Xiao, J., Wang, Y., and Huang, H. (2012) . Olfactory ensheathing cell neurorestorotherapy for amyotrophic lateral sclerosis patients, benefits from multiple transplantations. Cell Transplant. 20. (in press ). Chen, L., Huang, H., Zhang, J., Zhang, F., Liu, Y., Xi, H., Wang, H., Gu, Z., Song, Y., Li, Y., and Tan, K. (2007 
